1 / 19

COMMON TECHNICAL DOCUMENT

COMMON TECHNICAL DOCUMENT. / 19. ORIGIN OF CTD…. ICH. EWG. CTD. / 19. CTD IS A JOINT EFFORT OF 3 REGULATORY AGENCIES: 1. European Medicines Agency (EMEA, Europe ), 2. Food and Drug Administration (FDA, USA ) and

zalika
Download Presentation

COMMON TECHNICAL DOCUMENT

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. COMMON TECHNICAL DOCUMENT / 19

  2. ORIGIN OF CTD… ICH EWG CTD / 19

  3. CTD IS A JOINT EFFORT OF 3 REGULATORY AGENCIES: 1.European Medicines Agency (EMEA, Europe), 2. Food and Drug Administration (FDA, USA) and 3. Ministry of Health, Labour and Welfare (MHLW,Japan). CTD CTD is maintained by ICH through EWG. It has been adopted by several other countries including Canada and Switzerland. / 19

  4. Any guideline which is given by ICH passes through different steps. • These different steps are called STATUS of that GUIDELINE. Status of CTD STATUS FUNCTIONALITY STEP 4 STATUS ACHIEVED IN NOV.2000 IN 5TH ICH CONFERENCE IN SANDIEGO.. Step 1 Development of Consensus Step 2 Text released for consultation STEP 5 STATUS ACHIEVED IN MAY.2001 IN ICH MEETING IN TOKYO. Step 3 Consultation outside ICH Step 4 ICH guideline finalized GUIDANCE MADE AVAILABLE TO INDUSTRY IN OCTOBER 16,2001 BY FDA. Step 5 Implementation / 19

  5. SIGNIFICANCE OF CTD: Avoid generating and compiling different registration dossiers Common format will significantly reduce the time and resources Facilitates simultaneous submission in three regions Facilitates exchange of information among regulatory authorities Faster availability of new medicines. / 19

  6. STRUCTURE OF CTD: - Divided into various modules having different contents. / 19

  7. MODULE 1 1.REGIONAL INFO. 1.1 ToC NOT A PART OF CTD 2.1 CTD ToC PARTS OF CTD 2.2 CTD INTRODUCTION MODULE 2 2.4 NCO Max. 30 2.5CO Max. 30 pgs. 2.3 QOS 2.6 NCWTS 2.7 CWTS 100 - 150 pgs. 50 - 400 pgs. Max.40 or 80 pgs. MODULE 3 MODULE 4 MODULE 5 • Quality • 3.1 ToC 4 non clinical study reports 4.1 ToC 5 clinical study reports 5.1 ToC / 19

  8. Paper CTD eCTD Doc 1 File 1 File 2 Doc 2 Doc 3 Doc 4 File 3 File 4 / 19

  9. eCTD:electronic CTD • Developed by M2 EWG (Multidisciplinary 2 Expert Working Group) of ICH. Industry <-----> Message <------> Agency Paper submission has been replaced by electronic submission / 19

  10. Characteristics of eCTD:- 1. Files Referenced in the XML Backbone(s) (Extensible Markup Language) REASONS: 1.It manages the large data for the entire submission and for each document within the submission. 2.This XML backbone allows the eCTD submission to be viewed via a web browser and can be loaded on a Web server. / 19

  11. 2.The file formats that can be included in the eCTD are Portable Document Format (PDF) and XML. However other formatscan be used for graphs and images. JPEG PNG GIF -may be used for higher resolution. / 19

  12. 3. All eCTD Submissions Include Module 1 Module 1 Identifies following important information: • Company Name • Drug Name • Submission Type • Submission Date • Application Number • Sequence Number / 19

  13. Nomenclature for files and eCTD submission. EXAMPLE:- MODULE 2 FILE NOMENCLATURE AND eCTD submission / 19

  14. Agency Sites with eCTD submission Information FDA :http://www.fda.gov/cder/regulatory/ersr/ectd.htm EMEA(EU) : http://esubmission.eudra.org/ MHLW(JP):http://www.mhlw.go.jp/english/index.html / 19

  15. Summary CTD was introduced with the aim to harmonize submission of technical data for registration of human use in different regions. After 5 years of implementation of ctd,we can say that considerable harmonization has been achieved in various regions for submission of technical data. More and more regulatory agencies have started association with this implementation generated actually by ICH before 5 years back. / 19

  16. FOR EXAMPLE : TGA (AUSTRALIAN REGULATORY AGENCY) has started submission of technical data in the form of CTD. http://www.tga.gov.au/docs/html/eugctd.htmhttp://www.tga.gov.au/docs/pdf/euguide/tgamod1.pdf http://www.tga.gov.au/docs/pdf/euguide/ich/ctdm2quality.pdfhttp://www.tga.gov.au/docs/pdf/euguide/ich/ctdm2safety.pdf http://www.tga.gov.au/docs/pdf/euguide/ich/ctdm2efficacy.pdf AND TGA IS NOW WORKING ON A PROJECT TO IMPLEMENT eCTD for marketing authorization, NDA, ANDA AND DIFFERENT DOSSIER SUBMISSION. / 19

  17. Study questions: • What is CTD? What are the advantages of it? (uni. exam…2005) • COMMENT ON:‘CTD is a common guideline for WHO,ICH,MCA,EMEA & USFDA.’ (uni.exam…2006) 3. What is CTD? Why it is introduced? Who regulates it? Give diagrammatic representation, advantages and exclusions of it. (uni. exam…2007) / 19

  18. REFERENCES:- • www.ich.org • http://www.fda.gov/cder/regulatory/ersr/ectd.htm • http://esubmission.eudra.org/ • http://www.mhlw.go.jp/english/index.html • http://www.tga.gov.au/docs/html/eugctd.htm / 19

  19. THANKS

More Related